This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Elvanse (Lisdexamfetamine)
See parent — vyvanse.md
Aliases (9)
Overview
What is Elvanse (Lisdexamfetamine)?
Elvanse is the European brand name for lisdexamfetamine dimesylate (Vyvanse in the US), a prodrug of dextroamphetamine FDA-approved for ADHD and binge eating disorder. Inactive until enzymatic cleavage in red blood cells.
Key Benefits
Smooth ~12-hour ADHD coverage with reduced abuse potential due to prodrug design (cannot be effectively snorted/injected). Lower euphoria and crash than IR amphetamine. Approved for binge eating disorder in adults.
Mechanism of Action
Lisdexamfetamine is hydrolyzed by red blood cell peptidases to release dextroamphetamine, which then reverses DAT and NET to release dopamine and norepinephrine. Rate-limited bioactivation flattens plasma peaks.
Pharmacokinetics
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
References
Takeda Elvanse product page (UK)
UK Summary of Product Characteristics for Elvanse
View StudyEMA / national regulator product registration history
confirms Elvanse = lisdexamfetamine dimesylate identical to US Vyvanse
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.